IN THE CLAIMS

1. (currently amended) An isolated polypeptide of the severe acute respiratory syndrome (SARS) virus, wherein the polypeptide comprises a SARS virus Spike (S) polypeptide or a fragment thereof, comprising

   (a) amino acid sequence SEQ ID NO:6042,

   (b) an amino acid sequence having greater than 80% sequence identity to SEQ ID NO:6042; or

   (c) at least 10 consecutive amino acids of SEQ ID NO:6042.

2. (currently amended) The polypeptide of claim 1, wherein the fragment ~~comprises~~ is selected from the group consisting of the S1 domain (SEQ ID NO: 7307), S2 domain (SEQ ID NO: 7308), the receptor binding region of the S1 domain, the oligomerization domain regions of the S2 domain, the leucine zipper region of the S2 domain, the membrane anchor region of the S1 domain, the hydrophobic domain region of the S2 domain, the cytoplasmic tail region of the S2 domain ~~and/or~~ and any of the polypeptide sequences given in SEQ ID NOS: [[NOs:]] 7193-7194, 7196-7199, 7207-7223, 7398, 7399 and 8041-8240.

3. (currently amended) The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence selected from SEQ ID NOS: [[NO^{s}:]] 6042~~, or~~ and 9962.

4. (previously presented) The polypeptide of claim 1, wherein the polypeptide is in oligomeric form.

5. (previously presented) The polypeptide of claim 4, wherein the oligomer is a trimer.

6. (previously presented) The polypeptide of claim 1, wherein the polypeptide is a fusion peptide.

7. (previously presented) The polypeptide of claim 6, wherein the fusion peptide comprises the Spike protein (SEQ ID NO: 6042) or fragment thereof.

8. (currently amended) The polypeptide of claim 7, wherein the fusion peptide comprises a polypeptide selected from the group consisting of a tag sequence, a second SARS virus protein, a non-SARS virus protein, and a bacterial protein ~~and/or an adjuvant~~.

9-21. (canceled)

22. (currently amended) ~~A vaccine~~ An immunogenic composition ~~for the treatment or prevention of severe acute respiratory syndrome (SARS)~~, comprising an isolated or purified polypeptide comprising ~~the~~ a SARS virus Spike protein or a fragment thereof.

23. (currently amended) The ~~vaccine~~ immunogenic composition of claim 22, comprising an isolated polypeptide according to any one of claims 2 to 8 and 121 to 126.

24. (canceled)

25. (currently amended) The ~~vaccine~~ immunogenic composition of claim 22, further comprising an adjuvant.

26. (currently amended) The ~~vaccine~~ immunogenic composition of claim 25, wherein the adjuvant is an aluminium salt or is MF59.

27. (currently amended) The ~~vaccine~~ immunogenic composition of claim 22, further comprising ~~more than~~ at least one additional SARS virus ~~antigen~~ antigen.

28. (currently amended) The ~~vaccine~~ immunogenic composition of claim 27, wherein the additional SARS virus antigen is ~~antigens are~~ selected from the group consisting of an S antigen, an E antigen, an N antigen, and an M antigen.

29-93. (canceled)

94. (previously presented) An isolated polypeptide comprising an immunogenic, surface exposed fragment of the amino acid sequence SEQ ID NO: 6042.

95. (original) The polypeptide of claim 94, wherein said fragment does not include the last 50 amino acids of the C-terminus of SEQ ID NO: 6042.

96. (previously presented) The polypeptide of claim 94, wherein said fragment does not include a transmembrane domain region of SEQ ID NO: 6042.

97. (original) The polypeptide of claim 94, wherein said fragment does not include a C-terminus cytoplasmic domain of SEQ ID NO: 6042.

98. (original) The polypeptide of claim 94, wherein said fragment does not include a N-terminus signal sequence.

99-113. (canceled)

114. (currently amended) The ~~vaccine~~ immunogenic composition of claim [[23]] 133 further comprising an adjuvant.

115. (currently amended) The ~~vaccine~~ immunogenic composition of claim 114 wherein the adjuvant is selected from the group consisting of a detoxified bacterial ADP-ribosylating toxin, a non-toxic double mutant form of ~~*Bordella*~~ *Bordetella pertussis* toxoids, chitosan, MF59, aluminium, ~~and~~ an aluminium salt ~~or~~, and a SMIP.

116. (canceled)

117. (currently amended) A method of stimulating an immune response in ~~vaccinating~~ a

subject comprising administering to the subject ~~a vaccine~~ the immunogenic composition of claim 22.

118-120. (canceled)

121. (withdrawn-currently amended) The polypeptide of claim 8, wherein the second SARS virus protein comprises ORF1a (SEQ ID NO: 6039), ORF1b (SEQ ID NOS: [[NOs:]] 7188 and 7189), ORF1ab polyprotein (SEQ ID NO: 6041), Matrix protein (SEQ ID NO: 6046), Nucleocapsid protein (SEQ ID NOS: [[NOs:]] 6051 and 6052), 3CLp protease (SEQ ID NOS: [[NOs:]] 6569 and 9769), small membrane protein (SEQ ID NO: 6045), any of the hypothetical proteins given in SEQ ID NOS: [[NOs:]] 6050, 6049, 6048, 6047, 6044, 6043 and 6040, or a fragment thereof.

122. (withdrawn-currently amended) The polypeptide of claim 121, wherein the fragment of the second SARS virus protein comprises any of the polypeptides given in SEQ ID NOS: [[NOs:]] 2206-2224, 3020-3042, 7180-7817, 7257-7264, 9764-9765, or any of the T-cell epitopes given in SEQ ID NOS: [[NOs:]] 7400-8040, 8281-9752.

123. (withdrawn) The polypeptide of claim 8, wherein the non-SARS virus protein is derived from a coronavirus, influenza virus, rhinovirus, parainfluenza virus, respiratory syncytial virus, adenovirus and/or metapneumovirus.

124. (withdrawn) The polypeptide of claim 8, wherein the bacterial protein is a bacterial adhesion protein or fragment thereof.

125. (withdrawn) The polypeptide of claim 124, wherein the bacterial adhesion protein is NadA, YadA, USpA2 or a NadA-like protein.

126. (withdrawn-currently amended) The polypeptide of claim 124, wherein the fusion protein comprises an amino acid sequence given in any of SEQ ID NOS [[NOs]]: 7197-7206 or SEQ ID NOS [[NOs]]: 7302-7306.

127. (currently amended) ~~A vaccine~~ An immunogenic composition ~~for the treatment or prevention of severe acute respiratory syndrome (SARS)~~ comprising an isolated polypeptide, wherein the polypeptide comprises a fragment of SEQ ID NO:6042, wherein said fragment does not include up to 70 amino acids of the C-terminus.

128. (currently amended) The ~~vaccine~~ immunogenic composition of claim 127 further comprising the adjuvant MF59.

129. (previously presented) The polypeptide of claim 94, wherein said fragment does not include a transmembrane domain region and a C-terminal cytoplasmic domain of SEQ ID NO: 6042.

130. (previously presented) The polypeptide of claim 94 wherein the fragment does not include up to 70 amino acids of the C-terminus.

131. (currently amended) The polypeptide of claim 1, wherein the polypeptide comprising SEQ ID NO:6042 ~~said fragment~~ does not include a transmembrane domain region and a C-terminal cytoplasmic domain.

132. (currently amended) The polypeptide of claim 1 wherein the polypeptide comprising SEQ ID NO:6042 ~~fragment~~ does not include up to 70 amino acids of the C-terminus.

133. (new) The immunogenic composition of claim 22 wherein the SARS virus Spike (S) polypeptide or fragment comprises

(a) amino acid sequence SEQ ID NO:6042,

(b) an amino acid sequence have greater than 80% sequence identity to SEQ ID NO:6042; or

(c) at least 10 consecutive amino acids of SEQ ID NO:6042.

134. (new) A method of stimulating an immune response in a subject comprising administering to the subject the immunogenic composition of claim 133.